Modulation of 5-fluorouracil by 5-ethyl-2'deoxyuridine on cell lines expressing different dihydropyrimidine dehydrogenase activities

Anti-Cancer Drugs

Volumn 10, Issue 6, 1999, Pages 561-567

  Katona, Csilla ^d   Tímár, Ferenc ^d   Jeney, András ^c   Fischel, Jean L ^a   Milano, Gerard ^a   Pandi, Erzsébet ^b   Kralovánszky, Judit ^b  

^a CENTRE ANTOINE LACASSAGNE   (France)

^b NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^c SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^d NONE

Author keywords

5 Ethyl 2' deoxyuridine; 5 Fluorouracil modulation; Dihydropyrimidine dehydrogenase

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; DNA POLYMERASE; EDOXUDINE; FLUOROURACIL; PYRIMIDINE; PYRIMIDINE NUCLEOSIDE PHOSPHORYLASE; THYMIDINE KINASE; THYMIDYLATE SYNTHASE;

ARTICLE; CELL LINE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG METABOLISM; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PYRIMIDINE METABOLISM;

EID: 0032822795     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199907000-00008     Document Type: Article

References (34)

1. 1. Szabolcs A, Sági I, Ötvös L. Synthesis of 5-alkyl-2'-deoxyuridines. Carbohydrates, Nucleosides, Nucleotides 1975; 2: 197-211.
2. 2. Swierkowsi M, Kamac J, Chlopkiewicz B. The antitumour activity of certain substituted nucleosides, Pol J Pharmacol harm 1976; 28: 403-9.
3. 3. Jeney A, Barre E, Taylor GA, et al. 5-ethyl-2'-deoxyuridine: an explanation for its lack of cytotoxic action in vivo. Eur J Cancer Clin Oncol 1986; 12: 557-62.
4. 4. Sági J, Nowak R, Zmudzka B, et al. A study of substrate specificity of mammalian and bacterial DNA polymerases with 5-alkyl-2'-deoxyuridine 5 triphosphates. Biochim Biophys Acta 1980, 606: 196-202.
5. 5. Kopper L, Magyarosy E, Jeney A, et al. Potentiation of the antitumor action of 5-fluorouracil with 5-ethyl-2'-deoxyuridine in human colon tumor xenografts. Oncology 1984; 41: 155-8.
6. 6. Poon MA, O'Connel MJ, Moertel CG, et al. Biochemical modulation of 5-fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal cancer. J Clin Oncol 1989; 7: 1407-18.
7. 7. Van Groeningen J, Peters GJ, Leyva A, et al. Reversal of 5-fluorouracil induced myelosuppression by prolonged administration of high dose uridine. J Natl Cancer Inst 1989; 81: 157-62.
8. H. Kelsen DP, Martin D, O'Neil J, et al. Phase I trial of PN-401, an oral prodrug of uridine, to prevent toxicity from fluorouracil in patients with advanced cancer. J Clin Oncol 1997; 15: 1511-7.
9. 9 Milano G, Etienne MC. Dihydropyrimidine dehydrogenase (DPD) and clinical pharmacology of 5-fluorouracil. Anticancer Res 1994; 14: 2295-8.
10. 10. Etienne MC, Cheradame S, Fischel JL, et al. Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 1995; 13: 1663-70.
11. 11. Yee LK, Allegra CJ, Steinberg SM, et al. Decreased catabolism of fluorouracil in peripheral blood mononuclear cells during combination therapy with fluorouracil leucovorin and interferon α-2a. J Natl Cancer Inst 1992; 84: 1820-5.
12. 12. Katona Cs, Kralovánszky J, Rosta A, et al. Putative role of dihydropyrimidine dehydrogenase in the toxic side effects of 5-fluorouracil in colorectal cancer patients. Oncology 1998; 55: 468-75.
13. 13. Fischel JL, Etienne MC, Spector T, et al. Dihydropyrimidine dehydrogenase: a tumoral target for fluorouracil modulation. Clin Cancer Res 1995; 1: 991-6.
14. 14. Schilsky RL, Hohneker J, Ratain MJ, et al. Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer. J Clin Oncol 1998; 16: 1450-7.
15. 15. Kralovánszky J, Pandi E, Katona Cs, et al. Possible mechanisms playing a role in the enhancement of the antitumour effect of 5-FU by 5-ethyl-2'-deoxyuridine. Ann Oncol 1996; 7 (suppl 1): 67.
16. 16. Veres Zs, Szabolcs A, Szinai I, et al. The effect of 5-alkyl-pyrimidines and 5-alkyl pyrimidine nucleosides on the catabolism of 5-fluorouracil in vivo. In: van der Plaas HC, Örvös L, Simonyi M, eds. Bio-organic beterocycles. Amsterdam; Elsevier 1984: 339-43.
17. 17. Naguib FNM, Kouni MH, Cha S. Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res 1985; 45: 5405-12
18. 18. Sommadossi JP, Gewirtz DA, Diasio RB, et al. Rapid catabolism of 5-fluorouracil in freshly isolated rat hepatocytes as analyzed by high-performance liquid chromatography. J Biol Chem 1982; 257: 8171-6.
19. 19. Klemperer G, Haynes GR. Thymidine kinase in rat liver during development Biochem J 1968; 108: 541-5.
20. 20. Roberts DW. An isotopic assay for thymidylate synthetase. Biochemistry 1966; 5: 3546-8.
21. 21. Ashour OM, Naguib NM, Khalifa MM, et al. Enhancement of 5-fluoro2'-deoxyuridine antitumor efficacy by the uridine phosphorylase inhibitor 5-benzyloxy barbituric acid. Cancer Res 1995; 55: 1092-8.
22. 22. Piedbois P, Rougier P, Buyse M, et al, (Meta-analysis Group in Cancer) Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clinw Oncol 1998; 16: 301-8.
23. 23. Longo GSA, Izzo J, Chang YM, et al. Pretreatment of colon carcinoma cells with Tomudex enhances 5-fluorouracil cytotoxicity. Clin Cancer Res 1998, 4: 469-73.
24. 24. Tallarida RJ, Murray RB. eds. Manual of pharmacologic calculations, 2nd edn. New York: Springer Verlag 1987.
25. 4 Pteglu assays. In: Rustum Y, McGuire JJ, eds. The expanding role af folates and fluoropyrimidines in cancer chemotherapy. New York: Plenum Press 1988. 97-104.
26. 26. Armstrong RD, Diasio RB. Improved measurement of thymidilate synthetase activity by a modified tritium-release assay. J Biochem Biophys Methods 1982; 6: 141-7.
27. 27. Beck A, Etienne MC, Chédame JL, et al. A role of dihydropyrimidine dehydrogenase and thymidylate synthase in tumor sensitivity to fluorouracil. Eur J Cancer 1994; 30A: 1517-22.
28. 28. Diasio RB, Lu Z. Dihydropyrimidine dehydrogenase activity and 5-fluorouracil chemotherapy. J Clin Oncol 1994; 12: 2239-42.
29. 29. Lu Z, Zhang R, Capenter JT, et al Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer implication for 5-fluorouracil based chemotherapy. Clin Cancer Res 1998; 4: 325-9.
30. 30. Milano G, Etienne MC, Pierrefite V, et al. Dihydropyrimidine dehydrogenase deficiency and fluorouracil related toxicity. Br J Cancer 1999; 79: 627-30.
31. 31. Peters GJ, Van der Wilt CL, Van Groeningen CJ. Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase. Eur J Cancer 1994; 10: 1408-11.
32. 32. Mirjolet JF, Barberi-Heyob M, Merlin JL, et al. Thymidylate synthase expression and activity relation to S-phase parameters and 5-fluorouracil sensitivity. Br J Cancer 1998; 78: 62-8.
33. 33. Porter DJT, Chestnut WG, Merrill BM, et al. Mechanism-based inactivation of dihydropyrimidine dehydrogenase by 5-ethynyluracil. J Biol Chem 1992; 267: 5236-42.
34. 34. Baccanari DP, Davis ST, Knick VC, et al. 5-Ethynyluracil (776C85) a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil. Proc Natl Acad Sci USA 1993; 90: 11064-8.